SCHEMBL807761

SCHEMBL807761

Cc1ccncc1N1CC(C)(C)c2ccc(C(F)(F)F)cc2C1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 1/20 0.40
CYP17A1 P05093 4/20 0.39
PDE10A Q9Y233 2/20 0.38
PDE2A O00408 1/20 0.35
PDE7A Q13946 1/20 0.35
OPRL1 P41146 1/20 0.35
FPR1 P21462 1/20 0.35
FPR2 P25090 1/20 0.35
GRM2 Q14416 1/20 0.34
GPBAR1 Q8TDU6 1/20 0.34
PARP1 P09874 1/20 0.34
PARP10 Q53GL7 1/20 0.34
CYP1A2 P05177 1/20 0.34
METAP2 P50579 1/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
CDK5 Q00535 1/20 0.34
CDK5R1 Q15078 1/20 0.34
LCK P06239 1/20 0.34
KDR P35968 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15471699 0.85 CYP11B2 (0.44) CYP11B2PARP1PARP10KEAP1NFE2L2
SCHEMBL793449 0.81 PARP1 (0.42) CYP11B2CYP17A1PDE10APARP1PARP10
SCHEMBL793461 0.76 CYP11B2 (0.43) CYP11B2CYP17A1PDE10ANOTUM
SCHEMBL28805709 0.75 CYP17A1 (0.36) CYP17A1PDE10APDE2APDE7AGPBAR1
SCHEMBL22833462 0.74 SCN10A (0.42) CYP17A1PDE10APDE2APDE7AGPBAR1
SCHEMBL29382374 0.74 SCN10A (0.42) CYP17A1PDE10APDE2APDE7AGPBAR1
SCHEMBL793794 0.72 HTR2A (0.41) CYP11B2CYP17A1PDE10APDE2APDE7A
SCHEMBL16166494 0.71 RAB9A (0.39) CYP11B2OPRL1GRM2
SCHEMBL12315157 0.69 CYP17A1 (0.52) CYP17A1FPR1FPR2GRM2
SCHEMBL16166879 0.68 SLC6A9 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
WO-2012035078-A1 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B1 CYP11B2 30/4885CYP17A1 1/4885PDE10A 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.